CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa
RegulatoryMixedALD drugMeplyffaPositive
AI Analysis
Summary
Minoryx Therapeutics received a positive CHMP recommendation for its ALD neurological drug after multiple regulatory hurdles, while Zevra's Meplyffa was rejected by EU regulators despite prior US approval.
Outcome Details
Minoryx's ALD drug recommended for approval by CHMP; Zevra's Meplyffa rejected by EU regulators
Importance:8/10
Sentiment:
0.30
EU regulatory decisionCHMP recommendationneurological diseaserare diseaseregulatory setbacktransatlantic discrepancy
Read the original article
Published by Endpoints News on July 24, 2026 1:23 PM